SCHEMBL18271828

SCHEMBL18271828

CO[C@H]1C(O)[C@@H](COP(=O)(OC)OP(=O)(O)OP(=O)(O)O)O[C@H]1n1cnc2c(=O)[nH]c(N)nc21

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ TGM2 P21980 1/20 0.61
▸ NT5E P21589 1/20 0.61
▸ TAS1R3 Q7RTX0 2/20 0.59
▸ TAS1R1 Q7RTX1 2/20 0.59
▸ FUT5 Q11128 1/20 0.57
▸ IMPDH2 P12268 5/20 0.56
▸ KRAS P01116 3/20 0.56
▸ IMPDH1 P20839 1/20 0.56
▸ POLB P06746 1/20 0.54
▸ RNASEL Q05823 1/20 0.54
▸ P2RY2 P41231 1/20 0.53
▸ P2RY4 P51582 1/20 0.53
▸ P2RY6 Q15077 1/20 0.53
▸ HINT1 P49773 1/20 0.53
▸ DCPS Q96C86 1/20 0.52
▸ ENPP1 P22413 1/20 0.51
▸ P2RY1 P47900 1/20 0.51
▸ P2RY12 Q9H244 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26067682 0.94 TGM2 (0.69) TGM2NT5ETAS1R3TAS1R1FUT5
SCHEMBL21715305 0.94 TGM2 (0.69) TGM2NT5ETAS1R3TAS1R1FUT5
SCHEMBL21715304 0.94 TGM2 (0.69) TGM2NT5ETAS1R3TAS1R1FUT5
SCHEMBL20850065 0.93 TGM2 (0.68) TGM2NT5ETAS1R3TAS1R1FUT5
SCHEMBL18648315 0.93 NT5E (0.71) TGM2NT5ETAS1R3TAS1R1FUT5
SCHEMBL23149534 0.93 TGM2 (0.68) TGM2NT5ETAS1R3TAS1R1FUT5
SCHEMBL20850061 0.93 NT5E (0.71) TGM2NT5ETAS1R3TAS1R1FUT5
SCHEMBL15747230 0.93 TGM2 (0.68) TGM2NT5ETAS1R3TAS1R1FUT5
SCHEMBL2033285 0.93 TGM2 (0.68) TGM2NT5ETAS1R3TAS1R1FUT5
SCHEMBL720115 0.93 TGM2 (0.68) TGM2NT5ETAS1R3TAS1R1FUT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160348099-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS INC (US) 2016-12-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160348099-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, ADAR, NSUN3 TGM2 1916/4885NT5E 32/4885TAS1R3 1881/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback